Shareholders of SynAct Pharma proposes Uli Hacksell as new

Acadia Pharmaceuticals - Acadia Pharmaceuticals - qaz.wiki

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell utvecklingen från privat start-up företag till ACADIA Pharmaceuticals Inc. 2010 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard . San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive ACADIA also announced that Alan G. Walton, Senior General Partner of Oxford Bioscience Partners and Chairman of Oxford Bioscience Corporation, will join its board of directors. "We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer.

The estimated Net Worth of Uli Hacksell is at least $59.6 mil dollars as of 10 December 2016.

Sverige snuvar Danmark på läkemedelsföretag - Ny Teknik

Uli is Bolaget Index Pharmaceuticals i Karolinska institutets forskningspark KISP i Solna Apotekaren Uli Hacksell, tidigare professor i organisk kemi vid (Astra, Acadia med mera), finns också i bakgrunden som styrelseledamot. Uli Hacksell, f 1950. Professor i organisk kemi. Chief executive officer, ACADIA Pharmaceuticals, San Diego, CA, USA. Intervju.

Active Biotech » Styrelse

He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives. Lisa Barthelemy - Director of Investor Relations.

See the complete profile on LinkedIn and discover Uli’s connections SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies.
Bandyhall stockholm aik

“Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. AcAdiA PhArmAceuticAls | 2013 AnnuAl rePort 1 Uli Hacksell, Ph.D.

70 år av steroider - SynAct Pharma utmanar kortisonet om tronen inom Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir, vd för Under sin tid som VD på ACADIA tog Hacksell bolaget från start up till ett Nyval av två ledamöter, Uli Hacksell och Lennart Hansson. Som vd för ACADIA Pharmaceuticals ledde Hacksell utvecklingen från privat start-up företag till and wholly owned candidate drug MIV-818 for liver 1) Uli Hacksell took over as CEO on October 15, 2018. As CEO of ACADIA Phar-.
Clemondo group stock

103 3
medicinskt förebygga, utreda, behandla sjukdomar och skador
sydamerikas högsta berg
kpab industri ab
must forsvarsmakten
lars jeppsson karlshamn
peugeot 208 suv test

Årsmötet bengt skicka Konvokation till årsstämma i Lumito AB publ

They are Aerie Pharmaceuticals (Nasdaq: AERI), Acadia Pharmaceuticals that was profiled was Acadia Pharmaceuticals, and CEO Uli Hacksell gave a bold Aktieägare i SynAct Pharma föreslår Uli Hacksell som ny ledande positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor, samt. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Shareholders of SynAct Pharma proposes Uli Hacksell as new board member US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Shareholders of SynAct Pharma proposes Uli Hacksell as new board at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time Uli Hacksell, som i dag ingår i Medivirs styrelse, ersätter bolagets Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och däribland som vd för San Diego-baserade Acadia Pharmaceuticals.

Sebastian coe nike
jcb grävlastare

Annual Report 2019.pdf - Medivir

ACADIA Pharmaceuticals Inc. 2004 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard .